blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2499494

EP2499494 - REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.01.2018
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  03.02.2017
FormerGrant of patent is intended
Status updated on  25.01.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Alexion Pharmaceuticals, Inc.
100 College Street
New Haven, CT 06510 / US
[2017/10]
Former [2012/38]For all designated states
ALEXION PHARMACEUTICALS, INC.
352 Knotter Drive
Cheshire, CT 06410 / US
Inventor(s)01 / MOVALIA, Mayur
21 Rosebud Lane
Brewer, ME 04412 / US
02 / ILLINGWORTH, Andrea
150 Eaton Ridge
Holden, ME 04429 / US
03 / FAAS MCKNIGHT, Susan
14 Stonewood Drive
Old Lyme, CT 06371 / US
04 / ROTHER, Russell, P.
10325 Forest Meadow Drive
Oklahoma City, OK 73151 / US
 [2012/38]
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2017/10]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2012/38]Dempster, Robert Charles
D Young & Co LLP 120 Holborn
London EC1N 2DY / GB
Application number, filing date10829274.909.11.2010
[2017/10]
WO2010US55997
Priority number, dateUS20090280897P09.11.2009         Original published format: US 280897 P
[2012/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011057250
Date:12.05.2011
Language:EN
[2011/19]
Type: A1 Application with search report 
No.:EP2499494
Date:19.09.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 12.05.2011 takes the place of the publication of the European patent application.
[2012/38]
Type: B1 Patent specification 
No.:EP2499494
Date:08.03.2017
Language:EN
[2017/10]
Search report(s)International search report - published on:AU12.05.2011
(Supplementary) European search report - dispatched on:EP07.06.2013
ClassificationIPC:G01N33/577, G01N33/53, G01N33/50, G01N33/68
[2012/38]
CPC:
G01N33/56972 (EP,US); G01N33/50 (KR); G01N33/5094 (US);
A61K31/56 (EP,US); A61K31/727 (EP,US); A61K35/19 (US);
A61K38/196 (EP,US); A61K38/4886 (EP,US); A61P7/00 (EP);
A61P7/02 (EP); C07K16/40 (US); C12Q1/02 (KR);
G01N33/68 (KR); G01N33/6893 (EP,US); G01N33/86 (KR);
G01N2800/226 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/38]
Extension statesBA06.06.2012
ME06.06.2012
TitleGerman:REAGENZIEN UND VERFAHREN FÜR DEN NACHWEIS VON PNH-TYP-II-LEUKOZYTEN UND IHRE IDENTIFIZIERUNG ALS RISIKOFAKTOREN FÜR THROMBOTISCHE ERKRANKUNGEN[2012/38]
English:REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS[2012/38]
French:RÉACTIFS ET PROCÉDÉS DESTINÉS À DÉTECTER DES GLOBULES BLANCS ASSOCIÉS À UNE HPN DE TYPE II ET LEUR IDENTIFICATION COMME FACTEURS DE RISQUE POUR DES TROUBLES THROMBOTIQUES[2012/38]
Entry into regional phase06.06.2012National basic fee paid 
06.06.2012Search fee paid 
06.06.2012Designation fee(s) paid 
06.06.2012Examination fee paid 
Examination procedure06.06.2012Examination requested  [2012/38]
20.12.2013Amendment by applicant (claims and/or description)
13.05.2014Despatch of a communication from the examining division (Time limit: M04)
16.09.2014Reply to a communication from the examining division
30.01.2015Despatch of a communication from the examining division (Time limit: M04)
01.06.2015Reply to a communication from the examining division
28.07.2015Despatch of a communication from the examining division (Time limit: M04)
03.12.2015Reply to a communication from the examining division
22.09.2016Communication of intention to grant the patent
20.01.2017Fee for grant paid
20.01.2017Fee for publishing/printing paid
20.01.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.05.2014
Opposition(s)11.12.2017No opposition filed within time limit [2018/07]
Fees paidRenewal fee
26.11.2012Renewal fee patent year 03
27.11.2013Renewal fee patent year 04
26.11.2014Renewal fee patent year 05
30.11.2015Renewal fee patent year 06
28.11.2016Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.11.2010
AL08.03.2017
AT08.03.2017
CY08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
MK08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
TR08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
IE09.11.2017
LU09.11.2017
MT09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
[2020/33]
Former [2020/15]HU09.11.2010
AT08.03.2017
CY08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
MK08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
TR08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
IE09.11.2017
LU09.11.2017
MT09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2019/52]HU09.11.2010
AT08.03.2017
CY08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
MK08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
IE09.11.2017
LU09.11.2017
MT09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2019/46]HU09.11.2010
AT08.03.2017
CY08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
IE09.11.2017
LU09.11.2017
MT09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2019/31]HU09.11.2010
AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
IE09.11.2017
LU09.11.2017
MT09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/50]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
IE09.11.2017
LU09.11.2017
MT09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/45]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
IE09.11.2017
LU09.11.2017
MT09.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/43]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
LU09.11.2017
MT09.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/41]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
LU09.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/33]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
MC08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
CH30.11.2017
LI30.11.2017
Former [2018/14]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SI08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2018/09]AT08.03.2017
CZ08.03.2017
DK08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2017/51]AT08.03.2017
CZ08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SK08.03.2017
SM08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
PT10.07.2017
Former [2017/50]AT08.03.2017
CZ08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
PL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SK08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
Former [2017/49]AT08.03.2017
CZ08.03.2017
EE08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
RO08.03.2017
RS08.03.2017
SE08.03.2017
SK08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
IS08.07.2017
Former [2017/48]CZ08.03.2017
FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
RS08.03.2017
SE08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
Former [2017/41]FI08.03.2017
HR08.03.2017
LT08.03.2017
LV08.03.2017
NL08.03.2017
RS08.03.2017
SE08.03.2017
BG08.06.2017
NO08.06.2017
GR09.06.2017
Documents cited:Search[A]   D. ROBERT SUTHERLAND ET AL: "Diagnosing PNH with FLAER and multiparameter flow cytometry", CYTOMETRY PART B: CLINICAL CYTOMETRY, vol. 72B, no. 3, 1 May 2007 (2007-05-01), pages 167 - 177, XP055064574, ISSN: 1552-4949, DOI: 10.1002/cyto.b.20151 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1002/cyto.b.20151
 [A]   HALL CLAIRE ET AL: "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 102, no. 10, 15 November 2003 (2003-11-15), pages 3587 - 3591, XP002482083, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2003-01-0009 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood-2003-01-0009
International search[X]   RICHARDS, S. J. ET AL.: "Application of Flow Cytometry to the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria", CYTOMETRY, vol. 42, 2000, pages 223 - 233, XP008153703 [X]

DOI:   http://dx.doi.org/10.1002/1097-0320(20000815)42:4<223::AID-CYTO2>3.0.CO;2-D
 [X]   DWORACKI, G. ET AL.: "Flow cytometric analysis of CD55 and CD59 expression on blood cells in paroxysmal nocturnal haemoglobinuria", FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, vol. 43, no. 2, 2005, pages 117 - 120, XP008153705 [X]
 [X]   BRODKSY, R. A. ET AL.: "Improved Detection and Characterization of Paroxysmal Nocturnal Hemoglobinuria Using Fluorescent Aerolysin", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 114, 2000, pages 459 - 466, XP008153663 [X]
 [XP]   "Blood (ASHAnnual Meeting Abstracts)", 2009, article MOVALIA, M. K. ET AL.: "Identification and Clinical Significance of Type II Granulocytes Among Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Identified Using Multiparameter High-Sensitivity Flow Cytometry.", pages: 114, XP008153390 [XP]
 [A]   HALL, C. ET AL.: "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)", BLOOD, vol. 102, 2003, pages 3587 - 3591, XP002482083 [A]

DOI:   http://dx.doi.org/10.1182/blood-2003-01-0009
 [A]   "Blood (ASHAnnual Meeting.Abstracts)", 2006, article HILL, A. ET AL.: "The Incidence and Prevalence of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Survival of Patients in Yorkshire", pages: 108, XP008153661 [A]
 [A]   MOYO, V. M. ET AL.: "Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays", BRITISH JOURNAL OF HAEMATOLOGY, vol. 126, 2004, pages 133 - 138, XP008153402 [A]

DOI:   http://dx.doi.org/10.1111/j.1365-2141.2004.04992.x
by applicant  ROSSE, MEDICINE, vol. 76, 1997, pages 63 - 93
   NICHOLSON-WELLER ET AL., PROC NATL ACAD SCI USA, vol. 80, 1983, pages 5066 - 5070
   YAMASHINA ET AL., NENGL J MED, vol. 323, 1990, pages 1184 - 1189
   SUTHERLAND ET AL., AM J CLIN PATHOL, vol. 132, 2009, pages 564 - 572
   BRODSKY ET AL., AM J CLIN PATHOL, vol. 114, 2000, pages 459 - 466
   RICHARDS ET AL., CYTOMETRY, vol. 42, no. 4, 15 August 2000 (2000-08-15), pages 223 - 33
   HALL ET AL., BLOOD, vol. 102, no. 10, 15 November 2003 (2003-11-15), pages 3587 - 91
   HILL ET AL., BLOOD (ASH ANNUAL MEETING ABSTRACTS, 2006, pages 108
   MOYO ET AL., BR J HAEMATOL., vol. 126, no. 1, July 2004 (2004-07-01), pages 133 - 8
   JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
   RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
   VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
   STAELENS ET AL., MOL IMMUNOL, vol. 43, 2006, pages 1243 - 1257
   JAKOBOVITS ET AL., PROC. NATL. CAD. SCI. USA, vol. 90, 1993, pages 2551
   JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
   BRUGGEMANN ET AL., YEAR IN IMMUNOL., vol. 7, 1993, pages 33
   DUCHOSAL ET AL., NATURE, vol. 355, 1992, pages 258
   TAYLOR ET AL., NUCLEIC ACIDS RES., vol. 20, 1992, pages 6287
   CHEN ET AL., INT. IMMUNOL., vol. 5, 1993, pages 647
   TUAILLON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3720 - 4
   CHOI ET AL., NATURE GENETICS, vol. 4, 1993, pages 117
   LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 859
   TAYLOR ET AL., INTERNATIONAL IMMUNOLOGY, vol. 6, 1994, pages 579 - 591
   TUAILLON ET AL., J. IMMUNOL., vol. 154, 1995, pages 6453 - 65
   FISHWILD ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 845
   TUAILLON ET AL., EUR. J. IMMUNOL., vol. 10, 2000, pages 2998 - 3005
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.